Sugi Predict

Sugi Predict / Targets / PPM1B

PPM1B

Protein phosphatase 1B · O75688 · PPM1B on Sugi Atlas →

6,437 patent compounds predicted against PPM1B, 2,826 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2548229 SCHEMBL2548229 0.56 5/20
SCHEMBL819846 SCHEMBL819846 0.56 5/20
SCHEMBL1008906 SCHEMBL1008906 0.56 5/20
SCHEMBL3294090 SCHEMBL3294090 0.52 5/20
SCHEMBL238046 SCHEMBL238046 0.50 5/20
Demethyl-Cantharidin Demethyl-Cantharidin (SCHEMBL177729) 1.00 4/20
Demethyl-Cantharidin Demethyl-Cantharidin (SCHEMBL3187662) 1.00 4/20
Demethyl-Cantharidin Demethyl-Cantharidin (SCHEMBL3195020) 1.00 4/20
SCHEMBL727169 SCHEMBL727169 0.74 4/20
SCHEMBL728769 SCHEMBL728769 0.74 4/20
SCHEMBL1104061 SCHEMBL1104061 0.68 4/20
SCHEMBL3495128 SCHEMBL3495128 0.56 4/20
SCHEMBL3494928 SCHEMBL3494928 0.54 4/20
SCHEMBL3494947 SCHEMBL3494947 0.50 4/20
SCHEMBL1627201 SCHEMBL1627201 0.49 4/20
SCHEMBL3495018 SCHEMBL3495018 0.43 4/20
SCHEMBL3497073 SCHEMBL3497073 0.42 4/20
SCHEMBL3189399 SCHEMBL3189399 0.39 4/20
SCHEMBL3189406 SCHEMBL3189406 0.39 4/20
SCHEMBL3495456 SCHEMBL3495456 0.38 4/20

Clinical trials — most relevant to PPM1B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes PHASE2COMPLETED
Leniolisib for Immune Dysregulation in PIDs PHASE2ACTIVE_NOT_RECRUITING
Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome PHASE2WITHDRAWN
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120 PHASE1COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Quantification of GADD34 Expression in RA nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Immune Signature of Palmoplantar Pustulosis nanCOMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Study of Metabolic Modifications in Children With Noonan Syndrome nanCOMPLETED
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure nanUNKNOWN
Cardiovascular Effects of Empagliflozine nanUNKNOWN
Exome Sequencing for Atypical Femoral Fractures nanCOMPLETED
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
Study of Proteus Syndrome and Related Congenital Disorders nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PPM1B binder may also engage these)

ProteinNameSimilarity
O62830 — 1.000 O62830 →
PPM1A Protein phosphatase 1A 0.976 landscape →
P49443 — 0.976 P49443 →
P20650 — 0.974 P20650 →
P35814 — 0.973 P35814 →
O62829 — 0.972 O62829 →
Q28DF4 — 0.967 Q28DF4 →
P35815 — 0.964 P35815 →
P36993 — 0.957 P36993 →
Q8N3J5 — 0.955 Q8N3J5 →
Q8BXN7 — 0.953 Q8BXN7 →
A6K136 — 0.952 A6K136 →
O88506 — 0.951 O88506 →
Q2PC20 — 0.950 Q2PC20 →
Q863I2 — 0.949 Q863I2 →
PRKD1 Serine/threonine-protein kinase D1 0.949 landscape →
Q9Z1W9 — 0.948 Q9Z1W9 →
E1C1R4 — 0.948 E1C1R4 →
A0A8I5ZNK2 — 0.948 A0A8I5ZNK2 →
Q6P9R2 — 0.947 Q6P9R2 →
Q9P0J1 — 0.946 Q9P0J1 →
Q9ULR3 — 0.946 Q9ULR3 →
USP47 Ubiquitin carboxyl-terminal hydrolase 47 0.946 landscape →
D2XV59 — 0.946 D2XV59 →
ACACA Acetyl-CoA carboxylase 1 0.945 landscape →
Q3UV70 — 0.945 Q3UV70 →
P11029 — 0.945 P11029 →
P11497 — 0.945 P11497 →
Q5U2U0 — 0.944 Q5U2U0 →
Q28559 — 0.943 Q28559 →